124 related articles for article (PubMed ID: 8364527)
1. Feasibility of prophylaxis and therapy against gram-negative infections by human monoclonal antibodies.
Lang AB; Fürer E; Cryz SJ
FEMS Immunol Med Microbiol; 1993 Jun; 7(1):9-13. PubMed ID: 8364527
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
3. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic and protective properties of a murine lipopolysaccharide-specific monoclonal antibody in experimental Pseudomonas aeruginosa pneumonia in mice.
Oishi K; Sonoda F; Miwa H; Tanaka H; Watanabe K; Matsumoto K; Pollack M
Microbiol Immunol; 1991; 35(12):1131-41. PubMed ID: 1808464
[TBL] [Abstract][Full Text] [Related]
5. Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins.
Sawada S; Suzuki M; Kawamura T; Fujinaga S; Masuho Y; Tomibe K
J Infect Dis; 1984 Oct; 150(4):570-6. PubMed ID: 6436393
[TBL] [Abstract][Full Text] [Related]
6. Establishment of stable cell lines producing anti-Pseudomonas aeruginosa monoclonal antibodies and their protective effects for the infection in mice.
O'Oka H; Chonan E; Mizutani K; Fukuda T; Kuroiwa Y; Ono Y; Shigeta S
Microbiol Immunol; 1992; 36(12):1305-16. PubMed ID: 1287405
[TBL] [Abstract][Full Text] [Related]
7. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization.
Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ
Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420
[TBL] [Abstract][Full Text] [Related]
8. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.
Hemachandra S; Kamboj K; Copfer J; Pier G; Green LL; Schreiber JR
Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa. Vaccines and immunotherapy.
Pennington JE
Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838
[TBL] [Abstract][Full Text] [Related]
10. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
Zaidi TS; Priebe GP; Pier GB
Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa.
Sawada S; Kawamura T; Masuho Y; Tomibe K
J Infect Dis; 1985 Nov; 152(5):965-70. PubMed ID: 3930629
[TBL] [Abstract][Full Text] [Related]
12. Therapy of established experimental Pseudomonas aeruginosa infections with oral ciprofloxacin and five human monoclonal antibodies against lipopolysaccharide antigens.
Collins MS; Ladehoff D; Mehton NS
Antibiot Chemother (1971); 1991; 44():185-95. PubMed ID: 1801636
[No Abstract] [Full Text] [Related]
13. Use of passive immunotherapy in the treatment of experimental Pseudomonas aeruginosa infections in burns.
Neely AN; Holder IA
Antibiot Chemother (1971); 1987; 39():26-40. PubMed ID: 3118788
[No Abstract] [Full Text] [Related]
14. Impact of molecular biology on Pseudomonas aeruginosa immunization.
Pennington JE
J Hosp Infect; 1988 Feb; 11 Suppl A():96-102. PubMed ID: 2896754
[TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa antigens as potential vaccines.
Stanislavsky ES; Lam JS
FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
[TBL] [Abstract][Full Text] [Related]
16. Systemic and topical protection studies using Pseudomonas aeruginosa flagella in an ocular model of infection.
Rudner XL; Hazlett LD; Berk RS
Curr Eye Res; 1992 Aug; 11(8):727-38. PubMed ID: 1424719
[TBL] [Abstract][Full Text] [Related]
17. Passive immunisation against Pseudomonas aeruginosa recombinant flagellin in an experimental model of burn wound sepsis.
Faezi S; Sattari M; Mahdavi M; Roudkenar MH
Burns; 2011 Aug; 37(5):865-72. PubMed ID: 21334822
[TBL] [Abstract][Full Text] [Related]
18. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies.
Finke M; Muth G; Reichhelm T; Thoma M; Duchêne M; Hungerer KD; Domdey H; von Specht BU
Infect Immun; 1991 Apr; 59(4):1251-4. PubMed ID: 1706316
[TBL] [Abstract][Full Text] [Related]
19. X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa.
Zweerink HJ; Gammon MC; Hutchison CF; Jackson JJ; Pier GB; Puckett JM; Sewell TJ; Sigal NH
Infect Immun; 1988 May; 56(5):1209-14. PubMed ID: 3128480
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F.
Hancock RE; Mutharia LM; Mouat EC
Eur J Clin Microbiol; 1985 Apr; 4(2):224-7. PubMed ID: 2408887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
